Pergamum reports positive follow-up data from a Phase II clinical trial of PXL-01 for prevention of post-surgical adhesions

barbara.lempert STOCKHOLM – June 27, 2012. Pergamum AB announced today that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post-surgical adhesions. ...

Novo Nordisk steps away from now-controversial Paula Deen

Tracy Staton Novo Nordisk has backed away from Paula Deen. The drugmaker joins a laundry list of Deen partners who've called it quits, now that the celebrity chef has confessed ...

With lead drug from Pfizer, Esperion shares jump in expanded $70M biotech IPO

Ryan McBride Esperion Therapeutics got a warm reception after an upsized IPO that hauled in $ 70 million. The Plymouth, MI-based biotech company increased the offering size from 4.5 ...

Top-prescribing docs collect cash from drugmakers

Tracy Staton Doctors who prescribe certain brands the most also have financial ties to the companies that make them, a ProPublica investigation found. Coincidence? Experts ...

Top Medicare Prescribers Get Big Speaking Fees From Pharma

esilverman Here is another reason that US taxpayers may want to know why some doctors prescribe some drugs. Medicare Part D, as you know, helps cover the cost of many medicines ...

EU grants U.S. API makers exemption from certification rule

Eric Palmer The FDA has gotten the coveted waiver from the European Commission from its new rules for imported APIs less than two weeks before the rule is set to go into effect on July ...

Maine Votes In Favor Importing Drugs From Foreign Pharmacies

esilverman After months of debate over access to affordable medicines, the Maine legislature overwhelmingly voted in favor of a bill that will allow state residents to purchase ...

Can Novartis gain anything from its latest breakthrough drug win at the FDA?

John Carroll Novartis has nabbed its second breakthrough drug designation from the FDA, raising the prospect that it could shave some time off the regulatory process for the heart drug ...

Sarepta shares spike on upbeat results from DMD extension study

John Carroll Shares of Sarepta were boosted this morning after the biotech announced that it reaped another round of promising results from a closely-watched Phase IIb study of its ...

AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199

barbara.lempert AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia ...

Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215

barbara.lempert Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215 for the Treatment of Multiple Myeloma — ...

Trigemina Attracts $4.5 Million Funding From Current Investors and Chilean Government Grant

barbara.lempert      Proceeds to Support Phase II Study of Intranasal Oxytocin Therapy MORAGA, Calif., June 17, 2013 (GLOBE NEWSWIRE) — Trigemina, Inc., a biopharmaceutical ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS